Fundraising

Sareum Holdings PLC
14 April 2008


For immediate release                                              14 April 2008


                              SAREUM HOLDINGS PLC
                          ("Sareum" or "the Company")

                                  Fundraising

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, is pleased to announce that it has agreed to place, through its
broker, Dowgate Capital Stockbrokers Limited, 219,400,000 ordinary shares of
0.025p nominal value ("Ordinary Shares") at a price of 0.25p per share to raise
£548,500 before expenses. The funds raised from this share issue will be used to
provide additional working capital for the Company.

Following the issue of these shares, the Company's issued share capital will
consist of 818,097,713 Ordinary Shares. The Company does not hold any ordinary
shares in Treasury. Therefore the total number of ordinary shares with voting
rights is now 818,097,713. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the Financial Services Authority's Disclosure and Transparency
Rules.

Application has been made for the admission of 219,400,000 shares to trading on
AIM with admission expected to take place on 18 April 2008.

Commenting on the announcement, Sareum's Chief Executive Officer, Dr Tim
Mitchell, said: "We are pleased to have been able to raise funds in difficult
market conditions. This placing will provide valuable additional funds for the
business."


For further information:

Sareum Holdings plc                                            01223 497700

Tim Mitchell, Chief Executive Officer
Buchanan Communications                                       020 7466 5000

Tim Anderson, Mary-Jane Johnson
Grant Thornton Corporate Finance                              020 7383 5100

Philip Secrett, Colin Aaronson


Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer.  Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease.  Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression.  Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff.  Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.

Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein.  Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR.  For further information, please visit
www.sareum.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange